Acuta Capital Partners’s Oxford Immunotec Global OXFD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
– Sell
-386,100
Closed -$5.98M – 81
2017
Q1
$5.98M Sell
386,100
-84,734
-18% -$1.21M 1.42% 18
2016
Q4
$7.04M Buy
470,834
+63,019
+15% +$885K 2.62% 15
2016
Q3
$5.12M Sell
407,815
-9,463
-2% -$95K 1.92% 18
2016
Q2
$3.76M Buy
417,278
+109,234
+35% +$1.07M 1.8% 17
2016
Q1
$3.05M Buy
308,044
+117,944
+62% +$1.21M 1.71% 22
2015
Q4
$2.19M Buy
190,100
+5,354
+3% +$66.3K 1.05% 29
2015
Q3
$2.49M Sell
184,746
-12,934
-7% -$175K 1.44% 28
2015
Q2
$2.74M Sell
197,680
-24,546
-11% -$332K 1.69% 23
2015
Q1
$3.13M Buy
+222,226
New +$3.02M 2.64% 11

Other funds holding OXFD

Acuta Capital Partners's OXFD Position: Q2 2017 in Review

Acuta Capital Partners sold out of Oxford Immunotec Global (OXFD) in Q2 2017, closing a stake of 386,100 shares — an estimated $5.98M sold.

Acuta Capital Partners first reported a position in OXFD in Q1 2015 and held it in 9 quarters. The position peaked at $7.04M in Q4 2016. 75 funds tracked by Wall St. Rank hold OXFD as of Q2 2017.

  • Acuta Capital Partners reported no remaining Oxford Immunotec Global position as of Q2 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 386,100 Oxford Immunotec Global shares in Q2 2017, an estimated $5.98M.
  • Acuta Capital Partners first reported a position in Oxford Immunotec Global in Q1 2015 and held it in 9 quarters.
  • Acuta Capital Partners's Oxford Immunotec Global position peaked at $7.04M in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Oxford Immunotec Global as of Q2 2017.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.